Brett Monia, Ionis Pharmaceuticals CEO
September 26, 2023 07:13 AM EDT
R&D

Io­n­is plans NDA fil­ing for first in­de­pen­dent drug af­ter pos­i­tive da­ta read­out in rare ge­net­ic dis­or­der

Katherine Lewin

News Reporter

Io­n­is is an­oth­er step clos­er to the launch of its first in­de­pen­dent drug, tout­ing pos­i­tive Phase III da­ta for olezarsen in pa­tients with a rare …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

As­traZeneca CEO reaf­firms com­mit­ment to Chi­na fol­low­ing ex­ec­u­tive's de­ten­tion

Mer­ck, As­traZeneca tout Phase 3 win for can­cer-turned-rare dis­ease drug

Sanofi, Ope­nAI, For­ma­tion Bio de­but pa­tient re­cruit­ing tool, will use in Phase 3 mul­ti­ple scle­ro­sis stud­ies

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times